Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015 (2015), Article ID 163120, 7 pages
http://dx.doi.org/10.1155/2015/163120
Research Article

Urinary Angiopoietin-2 Is Associated with Albuminuria in Patients with Type 2 Diabetes Mellitus

1Department of Nephrology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, Hubei 430022, China
2Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China

Received 10 June 2014; Revised 8 September 2014; Accepted 18 September 2014

Academic Editor: Giuseppina T. Russo

Copyright © 2015 Shan Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. T. Lane, “Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective,” American Journal of Physiology—Renal Physiology, vol. 286, no. 3, pp. F442–F450, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. A. S. Woolf, L. Gnudi, and D. A. Long, “Roles of angiopoietins in kidney development and disease,” Journal of the American Society of Nephrology, vol. 20, no. 2, pp. 239–244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Karalliedde and G. Viberti, “Microalbuminuria and cardiovascular risk,” The American Journal of Hypertension, vol. 17, no. 10, pp. 986–993, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Advani and R. E. Gilbert, “The endothelium in diabetic nephropathy,” Seminars in Nephrology, vol. 32, no. 2, pp. 199–207, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. F.-C. Chang, T.-S. Lai, C.-K. Chiang et al., “Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease,” PLoS ONE, vol. 8, no. 3, Article ID e54668, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Nakagawa, T. Kosugi, M. Haneda, C. J. Rivard, and D. A. Long, “Abnormal angiogenesis in diabetic nephropathy,” Diabetes, vol. 58, no. 7, pp. 1471–1478, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Østerby, A. Hartmann, and H.-J. Bangstad, “Structural changes in renal arterioles in type I diabetic patients,” Diabetologia, vol. 45, no. 4, pp. 542–549, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Østerby, J. Asplund, H.-J. Bangstad et al., “Neovascularization at the vascular pole region in diabetic glomerulopathy,” Nephrology Dialysis Transplantation, vol. 14, no. 2, pp. 348–352, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Kanesaki, D. Suzuki, G. Uehara et al., “Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy,” The American Journal of Kidney Diseases, vol. 45, no. 2, pp. 288–294, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. N. H. Kim, K. B. Kim, D. L. Kim et al., “Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type 2 diabetes mellitus,” Diabetic Medicine, vol. 21, no. 6, pp. 545–551, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. H.-P. Hammes, J. Lin, P. Wagner et al., “Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy,” Diabetes, vol. 53, no. 4, pp. 1104–1110, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. P. C. Maisonpierre, C. Suri, P. F. Jones et al., “Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis,” Science, vol. 277, no. 5322, pp. 55–60, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. H. T. Yuan, E. V. Khankin, S. A. Karumanchi, and S. M. Parikh, “Angiopoietin 2 is a partial agonist/antagonist of tie2 signaling in the endothelium,” Molecular and Cellular Biology, vol. 29, no. 8, pp. 2011–2022, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. N. H. Kim, J. H. Oh, J. A. Seo et al., “Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy,” Kidney International, vol. 67, no. 1, pp. 167–177, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. M. E. Cooper, D. Vranes, S. Youssef et al., “Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes,” Diabetes, vol. 48, no. 11, pp. 2229–2239, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. S. L. Hoong, A. D. Blann, Y. C. Aun, B. Freestone, and G. Y. H. Lip, “Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention,” Diabetes Care, vol. 27, no. 12, pp. 2918–2924, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Dei Cas and L. Gnudi, “VEGF and angiopoietins in diabetic glomerulopathy: how far for a new treatment?” Metabolism: Clinical and Experimental, vol. 61, no. 12, pp. 1666–1673, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. D. R. Cha, Y. S. Kang, S. Y. Han et al., “Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats,” Journal of Endocrinology, vol. 183, no. 1, pp. 183–194, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Hovind, L. Tarnow, P. B. Oestergaard, and H.-H. Parving, “Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy,” Kidney International, Supplement, vol. 57, no. 75, pp. S56–S61, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Rasul, M. H. Reiter, A. Ilhan, K. Lampichler, L. Wagner, and A. Kautzky-Willer, “Circulating angiopoietin-2 and soluble Tie-2 in type 2 diabetes mellitus: a cross-sectional study,” Cardiovascular Diabetology, vol. 10, article 55, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Kümpers, S. David, M. Haubitz et al., “The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 68, no. 10, pp. 1638–1643, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Davis, A. dei Cas, D. A. Long et al., “Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia,” Journal of the American Society of Nephrology, vol. 18, no. 8, pp. 2320–2329, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. G. C. Viberti, R. J. Jarrett, R. D. Hill, A. Argyropoulos, U. Mahmud, and H. Keen, “Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus,” The Lancet, vol. 1, no. 8287, pp. 1430–1432, 1982. View at Publisher · View at Google Scholar · View at Scopus
  24. K. G. Alberti and P. Z. Zimmet, “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a who consultation,” Diabetic Medicine, vol. 15, pp. 539–553, 1998. View at Google Scholar
  25. “KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease,” American Journal of Kidney Diseases, vol. 49, no. 2, supplement 2, pp. S12–S154, 2007. View at Publisher · View at Google Scholar
  26. B. Rizkalla, J. M. Forbes, Z. Cao, G. Boner, and M. E. Cooper, “Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system,” Journal of Hypertension, vol. 23, no. 1, pp. 153–164, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. S. David, S. G. John, H. J. Jefferies et al., “Angiopoietin-2 levels predict mortality in CKD patients,” Nephrology, Dialysis, Transplantation, vol. 27, no. 5, pp. 1867–1872, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. R. C. Shroff, K. L. Price, M. Kolatsi-Joannou et al., “Circulating angiopoietin-2 is a marker for early cardiovascular disease in children on chronic dialysis,” PLoS ONE, vol. 8, no. 2, Article ID e56273, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. S. David, P. Kümpers, A. Lukasz et al., “Circulating angiopoietin-2 levels increase with progress of chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 25, no. 8, pp. 2571–2576, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. H. Rudolfsson, A. Johansson, I. F. Lissbrant, P. Wikström, and A. Bergh, “Localized expression of angiopoietin 1 and 2 may explain unique characteristics of the rat testicular microvasculature,” Biology of Reproduction, vol. 69, no. 4, pp. 1231–1237, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Maeshima and H. Makino, “Angiogenesis and chronic kidney disease,” Fibrogenesis & Tissue Repair, vol. 3, article 13, 2010. View at Publisher · View at Google Scholar
  32. S. Ogawa, K. Nako, M. Okamura et al., “A decline in glomerular filtration rate rather than renal arterial stenotic lesions, per se, predicts cardiovascular-renal events in type 2 diabetic patients,” Circulation Journal, vol. 77, no. 11, pp. 2816–2822, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. F.-C. Chang and S.-L. Lin, “The role of angiopoietin-2 in progressive renal fibrosis,” Journal of the Formosan Medical Association, vol. 112, no. 4, pp. 175–176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. H. S. Lim, G. Y. H. Lip, and A. D. Blann, “Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis,” Atherosclerosis, vol. 180, no. 1, pp. 113–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Okamoto, S.-I. Yamagishi, Y. Inagaki et al., “Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin,” The FASEB Journal, vol. 16, no. 14, pp. 1928–1930, 2002. View at Google Scholar · View at Scopus
  36. S. C. Satchell, K. L. Anderson, and P. W. Mathieson, “Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties,” Journal of the American Society of Nephrology, vol. 15, no. 3, pp. 566–574, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. S. C. Satchell and P. W. Mathieson, “Angiopoietins: microvascular modulators with potential roles in glomerular pathophysiology,” Journal of Nephrology, vol. 16, no. 2, pp. 168–178, 2003. View at Google Scholar · View at Scopus
  38. C. Dessapt-Baradez, A. S. Woolf, K. E. White et al., “Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease,” Journal of the American Society of Nephrology, vol. 25, no. 1, pp. 33–42, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. A. H. J. Salmon, C. R. Neal, L. M. Sage, C. A. Glass, S. J. Harper, and D. O. Bates, “Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx,” Cardiovascular Research, vol. 83, no. 1, pp. 24–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Lenz, T. Haak, J. Malek, H.-J. Gröne, H. Geiger, and J. Gossmann, “Vascular endothelial growth factor in diabetic nephropathy,” Kidney and Blood Pressure Research, vol. 26, no. 5-6, pp. 338–343, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Shimada, T. Baba, S. Neugebauer et al., “Plasma vascular endothelial growth factor in Japanese Type 2 diabetic patients with and without nephropathy,” Journal of Diabetes and its Complications, vol. 16, no. 6, pp. 386–390, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. A. D. Blann, F. M. Belgore, C. N. McCollum, S. Silverman, P. L. Lip, and G. Y. H. Lip, “Vascular endothelial growth factor and its receptor, Flt-I, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes,” Clinical Science, vol. 102, no. 2, pp. 187–194, 2002. View at Publisher · View at Google Scholar · View at Scopus